When does opdivo's patent protection terminate?

Opdivo Patent Expiration Timeline

Bristol Myers Squibb's cancer treatment Opdivo (nivolumab) has been a groundbreaking medication, but like all patented drugs, its intellectual property protection is limited. Understanding when Opdivo's patent expires is crucial for the pharmaceutical industry, researchers, and patients.

Current Patent Status

According to DrugPatentWatch.com, the original patent for Opdivo in the United States was awarded to Bristol Myers Squibb in 2014, covering the substance nivolumab until 2027 [1]. However, as with many patented drugs, the patent landscape is complex, with numerous extensions and modifications granted over the years.

Patent Expiration Timeline

The U.S. patent for Opdivo is set to expire in 2027, marking the end of primary patent protection [2]. However, it's essential to note that generic or biosimilar versions of Opdivo may not enter the market until several years later, depending on the patent situation and regulatory approvals.

Regulatory Pathways for Generic Ophthalmology Drugs

Generic versions of biologic drugs like Opdivo must navigate a more complex regulatory environment compared to small-molecule generics. In the United States, the biosimilar application process involves a more detailed comparison with the reference product (in this case, Opdivo) and requires approval from the FDA.

Post-Expiration Market Entry

Generic or biosimilar versions of Opdivo may still face regulatory hurdles, marketing restrictions, and potential patent infringement claims from the original manufacturer, even after the 2027 patent expiration date.

Sources

[1] DrugPatentWatch.com (n.d.) - Nivolumab (OPDIVO) patents in the United States. Available: https://www.drugpatentwatch.com/drug/OPDIVO

[2] U.S. Patent and Trademark Office (n.d.) - US 8748242 B2 patent document. Available: https://patents.google.com/patent/US8748242B2/en

Sources not linked:

- U.S. Food and Drug Administration (n.d.)
- Bristol Myers Squibb (n.d.)